CEACAM5 and neoplasm: A new immunotherapy known as CEA-TCB, an IgG-based T-cell bispecific antibody (TCB) reroutes T cells to tumor cells that express the carcinoembryonic antigen (CEA) glycoprotein on their cell surface, regardless of the T cell receptor specificity of the redirected T cells.